I have received all of my order plus the bonus pills. You not only met my
expectations but greatly exceeded them!
You properly set my expectations by providing me all the information that I would
need during the ordering process and then followed up regularly to insure that all
was occurring as it should.
Your focus on customer service is outstanding and has won me over as a long time
customer. I have already recommended you to two of my friends and will continue to
do so in the future. I am also very pleased with the quality of your product and
accompanying reference materials that I received with my order.
I will do all of my medical business through your firm from this point forward.
Thank you for your proactive efforts and strong customer focused business
practices. I can honestly say my purchase experience has been outstanding!
- Sincerely, Lloyd
Aurobindo Pharma receives final approval for Lamivudine+Zidovudine Tablets - Equity Bulls
Zee NewsAurobindo Pharma receives final approval for Lamivudine+Zidovudine TabletsEquity BullsAurobindo Pharma Limited has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market for Lamivudine & Zidovudine tablets USP 150/300 mg (ANDA 202418) and is ready for launch.
Lupin, Aurobindo get USFDA nod for HIV drug - Economic Times
Lupin, Aurobindo get USFDA nod for HIV drugEconomic TimesLupin Pharmaceuticals Inc, a subsidiary of Lupin Ltd, has received final approval from US Food and Drug Administration (USFDA) for its generic Lamivudine and Zidovudine combination tablet in strength of 150mg/300 mg, Lupin said in a statement.
LANDMARK HIV DRUG'S PATENT EXPIRES TODAY - U-T San Diego
LANDMARK HIV DRUG'S PATENT EXPIRES TODAYU-T San DiegoThe FDA approved Combivir (lamivudine/zidovudine) in 1997, greatly changing the treatment of HIV/AIDS.
Patent expires of landmark HIV drug Combivir - U-T San Diego
Patent expires of landmark HIV drug CombivirU-T San DiegoThe FDA approved Combivir (lamivudine/zidovudine) in 1997, greatly changing the treatment of HIV/AIDS.
South Africa exceeds 2007-11 treatment targets by 50% - aidsmap
South Africa exceeds 2007-11 treatment targets by 50%aidsmapCrude estimates of numbers of public sector patients on treatment in each quarter were calculated according to lamivudine (3TC, Epivir) sales figures from Aspen Pharmacare, which supplied 80% of lamivudine to the public sector until recently.